The efficacy of ponatinib for patients with CML with resistance to prior tyrosine kinase inhibitor therapy could be balanced against the risk of arterial occlusive disease by reduced dose intensity when a response is attained. Professional illustration by Patrick Lane, ScEYEnce Studios.